Qlucore AB

Equities

QCORE

SE0016829824

Software

Market Closed - Nasdaq Stockholm 10:47:33 2024-04-19 am EDT 5-day change 1st Jan Change
8.45 SEK +2.42% Intraday chart for Qlucore AB -2.87% +10.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Qlucore Announces the Launch of the Qlucore Omics Explorer Cloud Version CI
Qlucore AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Qlucore AB Announces Grant from EU CI
Qlucore Submits Technical Documentation for CE Marking of Pediatric Leukemia Medical Device MT
Qlucore Diagnostics for Pediatric Leukemia Takes A Significant Step Closer to Ce Marking CI
Sahlgrenska Hospital Invests in Precision Diagnostics with Qlucore AB Insights CI
Boehringer Ingelheim Signs Two-Year Agreement with Qlucore CI
Qlucore Announces Swedish Innovation Evaluated for Clinical Diagnosis of Pediatric Leukemia CI
Qlucore AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Qlucore AB Appoints Lars Höckenström as A Member of the Board of Directors CI
Qlucore AB Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
Qlucore AB Reports Earnings Results for the Fourth Quarter Ended April 30, 2023 CI
Qlucore AB Reports Earnings Results for the Full Year Ended April 30, 2023 CI
Qlucore Launches Qlucore Omics Explorer Version 3.9 CI
Qlucore AB Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023 CI
Qlucore AB Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022 CI
Qlucore Software Used in New Project to Prevent Cardiovascular Diseases CI
Qlucore Receives Patent in Europe CI
Qlucore Ab Reports Earnings Results for the First Quarter Ended July 31, 2022 CI
Qlucore to Develop Diagnostics Product for Two Blood Cancer Types MT
Qlucore Expands Its Leukemia Diagnostics Solution CI
Certain Shares of Qlucore AB are subject to a Lock-Up Agreement Ending on 5-AUG-2022. CI
Qlucore Ab Reports Earnings Results for the Full Year Ended April 30, 2022 CI
Qlucore Announces New Collaboration in the Field of Precision Diagnostics to Develop Solutions for Improved Clinical Diagnostics of Bladder Cancer CI
Qlucore Names Erik Söderbäck as Head of Diagnostics Sales CI
Chart Qlucore AB
More charts
Qlucore AB is a Sweden-based provider of new generation of intuitive bioinformatics software for research and precision and companion diagnostics. Its mission is to make it easier to analyze the vast amounts of complex data generated by innovations in genomics and proteomics. This is done by providing visualization-based analysis data tools for bioinformatics for research and precision diagnostics. The tools are so easy to use that researchers, technicians and doctors can easily interpret and explore their data sets. Qlucore Diagnostics software is a platform for multi-omics companion and precision diagnostics. AI-driven, disease-specific machine learning-based classification models are combined with patient-friendly visualizations in an easy-to-use and cost-effective software solution that integrates with a wide range of data-generating technologies and instruments. Qlucore was founded in 2007 by researchers at the departments of mathematics and clinical genetics at Lund University.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. QCORE Stock
  4. News Qlucore AB
  5. Qlucore to Develop Diagnostics Product for Two Blood Cancer Types